In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I.
The activity of LJC10,627 was compared with the activities of imipenem and other antibiotics. LJC10,627 was more active against most members of the family Enterobacteriaceae, Pseudomonas spp., and Acinetobacter spp. but slightly less active than imipenem against staphylococci and streptococci. LJC10,627 showed stability to mouse dehydropeptidase I and was more effective in vivo than imipenem plus cilastatin against gram-negative bacterial infections and as effective against staphylococcal infections.
Petersen
P J
PJ
Medical Research Division, American Cyanamid Co., Pearl River, New York 10965.
Jacobus
N V
NV
Weiss
W J
WJ
Testa
R T
RT
D000583:Amikacin / Q000494:pharmacology; D000818:Animals; D001424:Bacterial Infections / Q000188:drug therapy; D001441:Bacteroides fragilis / Q000187:drug effects; D015780:Carbapenems / Q000494:pharmacology* / Q000627:therapeutic use; D002442:Ceftazidime / Q000494:pharmacology; D015377:Cilastatin / Q000494:pharmacology / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000494:pharmacology; D004150:Dipeptidases / Q000378:metabolism*; D004359:Drug Therapy, Combination / Q000494:pharmacology / Q000627:therapeutic use; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D015378:Imipenem / Q000494:pharmacology / Q000627:therapeutic use; D007711:Klebsiella pneumoniae / Q000187:drug effects; D008795:Metronidazole / Q000494:pharmacology; D051379:Mice; D008826:Microbial Sensitivity Tests; D010878:Piperacillin / Q000494:pharmacology; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D013845:Thienamycins
D015780:Carbapenems; D013845:Thienamycins; D008795:Metronidazole; D015377:Cilastatin; D002939:Ciprofloxacin; D015378:Imipenem; D000583:Amikacin; D002442:Ceftazidime; D004150:Dipeptidases; C038937:dipeptidase; D010878:Piperacillin; C065257:biapenem